Literature DB >> 2069387

Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid.

R J Wallace1, B A Brown, G O Onyi.   

Abstract

MICs of imipenem, cefoxitin, cefmetazole, and amoxicillin-clavulanic acid were determined against 100 strains of Mycobacterium fortuitum and 200 strains of Mycobacterium chelonae. Imipenem and cefmetazole were more active against M. fortuitum than cefoxitin was, and imipenem (which inhibited 39% of strains at 8 micrograms/ml) was the only beta-lactam active against M. chelonae subsp. chelonae.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2069387      PMCID： PMC245098          DOI： 10.1128/AAC.35.4.773

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  In vitro susceptibility of Mycobacterium fortuitum to cefoxitin.

Authors:  M H Cynamon; A Patapow
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

2.  In vitro susceptibility of mycobacterium fortuitum and mycobacterium chelonei to cefoxitin.

Authors:  M Casal; F Rodríguez
Journal:  Tubercle       Date:  1982-06

3.  Disk diffusion testing with polymyxin and amikacin for differentiation of Mycobacterium fortuitum and Mycobacterium chelonei.

Authors:  R J Wallace; J M Swenson; V A Silcox; R C Good
Journal:  J Clin Microbiol       Date:  1982-12       Impact factor: 5.948

4.  Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei.

Authors:  J R Dalovisio; G A Pankey; R J Wallace; D B Jones
Journal:  Rev Infect Dis       Date:  1981 Sep-Oct

5.  In vitro susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to cefmetazole.

Authors:  M J Casal; F C Rodriguez; M C Benavente
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

6.  In vitro susceptibility of Mycobacterium fortuitum to amoxicillin or cephalothin in combination with clavulanic acid.

Authors:  M H Cynamon; G S Palmer
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

7.  Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities.

Authors:  R J Wallace; J M Swenson; V A Silcox; M G Bullen
Journal:  J Infect Dis       Date:  1985-09       Impact factor: 5.226

8.  In vitro susceptibility of Mycobacterium fortuitum to N-formimidoyl thienamycin and several cephamycins.

Authors:  M H Cynamon; G S Palmer
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

Review 9.  Spectrum of disease due to rapidly growing mycobacteria.

Authors:  R J Wallace; J M Swenson; V A Silcox; R C Good; J A Tschen; M S Stone
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

10.  Identification of clinically significant Mycobacterium fortuitum complex isolates.

Authors:  V A Silcox; R C Good; M M Floyd
Journal:  J Clin Microbiol       Date:  1981-12       Impact factor: 5.948
View more
  31 in total

1.  Multisite reproducibility of Etest for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum.

Authors:  G L Woods; J S Bergmann; F G Witebsky; G A Fahle; B Boulet; M Plaunt; B A Brown; R J Wallace; A Wanger
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society.

Authors: 
Journal:  Thorax       Date:  2000-03       Impact factor: 9.139

3.  Sequence-based identification of Mycobacterium species using the MicroSeq 500 16S rDNA bacterial identification system.

Authors:  J B Patel; D G Leonard; X Pan; J M Musser; R E Berman; I Nachamkin
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

Review 4.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

5.  In Vitro Comparison of Ertapenem, Meropenem, and Imipenem against Isolates of Rapidly Growing Mycobacteria and Nocardia by Use of Broth Microdilution and Etest.

Authors:  Barbara A Brown-Elliott; Jessica Killingley; Sruthi Vasireddy; Linda Bridge; Richard J Wallace
Journal:  J Clin Microbiol       Date:  2016-04-06       Impact factor: 5.948

Review 6.  Recent changes in taxonomy and disease manifestations of the rapidly growing mycobacteria.

Authors:  R J Wallace
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

7.  Recurrent catheter-related infection caused by a single clone of Mycobacterium chelonae with two colonial morphotypes.

Authors:  P R Hsueh; L J Teng; P C Yang; Y C Chen; S W Ho; K T Luh
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

Review 8.  Skin and Soft Tissue Infections Due to Nontuberculous Mycobacteria.

Authors:  Elizabeth Ann Misch; Christopher Saddler; James Muse Davis
Journal:  Curr Infect Dis Rep       Date:  2018-03-19       Impact factor: 3.725

9.  Cardiac device infections due to Mycobacterium fortuitum.

Authors:  Marion Hemmersbach-Miller; Miguel A Cárdenes-Santana; Alicia Conde-Martel; José A Bolaños-Guerra; María I Campos-Herrero
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-05       Impact factor: 2.471

10.  Clinical and radiological features of pulmonary disease caused by rapidly growing mycobacteria in cancer patients.

Authors:  K Jacobson; R Garcia; H Libshitz; E Whimbey; K Rolston; D Abi-Said; I Raad
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-09       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.